<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39477428</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>30</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1791-7549</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>6</Issue><PubDate><Year>2024</Year><Season>Nov-Dec</Season></PubDate></JournalIssue><Title>In vivo (Athens, Greece)</Title><ISOAbbreviation>In Vivo</ISOAbbreviation></Journal><ArticleTitle>Long-term Impacts of Long COVID: Increased Incidence of Cardiomyopathies, Joint Diseases, and Psychoanxiety Disorders.</ArticleTitle><Pagination><StartPage>3022</StartPage><EndPage>3032</EndPage><MedlinePgn>3022-3032</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.21873/invivo.13786</ELocationID><Abstract><AbstractText Label="BACKGROUND/AIM" NlmCategory="OBJECTIVE">The COVID-19 pandemic has intensified inquiries into the interplay between diabetes and disease severity, and the long-term impact of long-COVID. This study specifically explored the implications of different antithrombotic treatments on COVID-19 patients. It aimed to assess the long-term efficacy and safety of Vitamin K antagonists (VKA) and direct oral anticoagulants (DOACs) in mitigating thromboembolic complications in COVID-19 patients.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">We conducted a study on 157 patients diagnosed with COVID-19 from August 2021 to August 2023. The study evaluated shifts in anticoagulant therapy recommendations, tracking the transition from VKA to DOACs, and analyzed associated health outcomes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A significant shift from VKA to DOACs prescriptions was observed, especially in high-risk patients. Despite the change in antithrombotic treatments, incidences of varices and varices with hemorrhoids increased by 2.6% and 3.2%, respectively. Long-COVID was also linked to higher occurrences of diabetes and gastrointestinal diseases. Joint diseases rose by 14%, indicating persistent inflammation. Cardiomyopathies increased by 3.9%, predominantly in high-risk groups, and psychoanxiety disorders surged by 39.5%, highlighting the need for further research. DOAC usage was more common in older age groups, with a 10.2% increase in recommendations among high-risk patients (p&lt;0.05).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The study underscores the evolving landscape of antithrombotic therapy in managing COVID-19 complications. Despite the increased use of DOACs, the rise in various health conditions suggests the necessity for personalized treatment strategies tailored to patient risk profiles.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moldovan</LastName><ForeName>Andrada Florina</ForeName><Initials>AF</Initials><AffiliationInfo><Affiliation>Doctoral School, Faculty of Medicine and Pharmacy, University of Oradea, Oradea, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghitea</LastName><ForeName>Timea Claudia</ForeName><Initials>TC</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, Oradea, Romania; timea.ghitea@csud.uoradea.ro.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Babe&#x219;</LastName><ForeName>Katalin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Doctoral School, Faculty of Medicine and Pharmacy, University of Oradea, Oradea, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manole</LastName><ForeName>Felicia</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, Oradea, Romania.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Greece</Country><MedlineTA>In Vivo</MedlineTA><NlmUniqueID>8806809</NlmUniqueID><ISSNLinking>0258-851X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>12001-79-5</RegistryNumber><NameOfSubstance UI="D014812">Vitamin K</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="Y">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009202" MajorTopicYN="Y">Cardiomyopathies</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013923" MajorTopicYN="N">Thromboembolism</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014812" MajorTopicYN="N">Vitamin K</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">DOACs</Keyword><Keyword MajorTopicYN="N">cardiomyopathies</Keyword></KeywordList><CoiStatement>The Authors declare no conflicts of interest in relation to this study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>31</Day><Hour>4</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>31</Day><Hour>4</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>30</Day><Hour>21</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>11</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39477428</ArticleId><ArticleId IdType="doi">10.21873/invivo.13786</ArticleId><ArticleId IdType="pii">38/6/3022</ArticleId><ArticleId IdType="pmc">PMC11535937</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bootun R, Burrows M, Chowdhury MM, Stather PW, Al-Jundi W. The risk of harm whilst waiting for varicose veins procedure. Phlebology. 2023;38(1):22&#x2013;27. doi: 10.1177/02683555221141824.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/02683555221141824</ArticleId><ArticleId IdType="pmc">PMC9713534</ArticleId><ArticleId IdType="pubmed">36441941</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemorrhoid Treatment, Vascular Institute of Virginia. Available at: https://vavascularinstitute.com/portfolio/hemorrhoid-treatment/ [Last accessed on December 4, 2022]</Citation></Reference><Reference><Citation>Hu WS, Lin CL. Hemorrhoid is associated with increased risk of peripheral artery occlusive disease: A nationwide cohort study. J Epidemiol. 2017;27(12):574&#x2013;577. doi: 10.1016/j.je.2016.12.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.je.2016.12.015</ArticleId><ArticleId IdType="pmc">PMC5623014</ArticleId><ArticleId IdType="pubmed">28268046</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahenthiran AK, Natarajan JP, Bertges DJ, Huffman KM, Eldrup-Jorgensen J, Lemmon GW. Impact of COVID-19 on the Society for Vascular Surgery Vascular Quality Initiative Venous Procedure Registries (varicose vein and inferior vena cava filter) J Vasc Surg Venous Lymphat Disord. 2021;9(5):1093&#x2013;1098. doi: 10.1016/j.jvsv.2021.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jvsv.2021.01.002</ArticleId><ArticleId IdType="pmc">PMC7816572</ArticleId><ArticleId IdType="pubmed">33482377</ArticleId></ArticleIdList></Reference><Reference><Citation>The diabetes pandemic. Lancet 378(9786) The diabetes pandemic. Lancet. 2011;378(9786):99. doi: 10.1016/S0140-6736(11)61068-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(11)61068-4</ArticleId><ArticleId IdType="pubmed">21742159</ArticleId></ArticleIdList></Reference><Reference><Citation>Moldovan AF, Moga I, Moga T, Ghitea EC, Babes K, Ghitea TC. Assessing the risk of stroke in the elderly in the context of long-COVID, followed through the lens of family medicine. In Vivo. 2023;37(5):2284&#x2013;2295. doi: 10.21873/invivo.13331.</Citation><ArticleIdList><ArticleId IdType="doi">10.21873/invivo.13331</ArticleId><ArticleId IdType="pmc">PMC10500484</ArticleId><ArticleId IdType="pubmed">37652474</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortes Garcia M, Sierra Moros MJ, Santa-Olalla Peralta P, Hernandez-Barrera V, Jimenez-Garcia R, Pachon I. Clinical characteristics and outcomes of diabetic patients who were hospitalised with 2009 pandemic influenza A H1N1 infection. J Infect. 2012;64(2):218&#x2013;224. doi: 10.1016/j.jinf.2011.11.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2011.11.022</ArticleId><ArticleId IdType="pubmed">22138602</ArticleId></ArticleIdList></Reference><Reference><Citation>Allard R, Leclerc P, Tremblay C, Tannenbaum TN. Diabetes and the severity of pandemic influenza A (H1N1) infection. Diabetes Care. 2010;33(7):1491&#x2013;1493. doi: 10.2337/dc09-2215.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc09-2215</ArticleId><ArticleId IdType="pmc">PMC2890346</ArticleId><ArticleId IdType="pubmed">20587722</ArticleId></ArticleIdList></Reference><Reference><Citation>Gentile S, Strollo F, Ceriello A. COVID-19 infection in Italian people with diabetes: Lessons learned for our future (an experience to be used) Diabetes Res Clin Pract. 2020;162:108137. doi: 10.1016/j.diabres.2020.108137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabres.2020.108137</ArticleId><ArticleId IdType="pmc">PMC7270733</ArticleId><ArticleId IdType="pubmed">32259611</ArticleId></ArticleIdList></Reference><Reference><Citation>Dal Canto E, Ceriello A, Ryd&#xe9;n L, Ferrini M, Hansen TB, Schnell O, Standl E, Beulens JW. Diabetes as a cardiovascular risk factor: An overview of global trends of macro and micro vascular complications. Eur J Prevent Cardiol. 2019;26(2_suppl):25&#x2013;32. doi: 10.1177/2047487319878371.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2047487319878371</ArticleId><ArticleId IdType="pubmed">31722562</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghitea TC, Aleya L, Tit DM, Behl T, Stoicescu M, Sava C, Iovan C, El-Kharoubi A, Uivarosan D, Pallag A, Bungau S. Influence of diet and sport on the risk of sleep apnea in patients with metabolic syndrome associated with hypothyroidism &#x2014; a 4-year survey. Environ Sci Pollut Res. 2022;29(16):23158&#x2013;23168. doi: 10.1007/s11356-021-17589-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11356-021-17589-x</ArticleId><ArticleId IdType="pubmed">34802081</ArticleId></ArticleIdList></Reference><Reference><Citation>Danciu AM, Ghitea TC, Bungau AF, Vesa CM. The relationship between oxidative stress, selenium, and cumulative risk in metabolic syndrome. In Vivo. 2023;37(6):2877&#x2013;2887. doi: 10.21873/invivo.13406.</Citation><ArticleIdList><ArticleId IdType="doi">10.21873/invivo.13406</ArticleId><ArticleId IdType="pmc">PMC10621440</ArticleId><ArticleId IdType="pubmed">37905638</ArticleId></ArticleIdList></Reference><Reference><Citation>Muniyappa R, Gubbi S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. Am J Physiol Endocrinol Metab. 2020;318(5):E736&#x2013;E741. doi: 10.1152/ajpendo.00124.2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpendo.00124.2020</ArticleId><ArticleId IdType="pmc">PMC7191633</ArticleId><ArticleId IdType="pubmed">32228322</ArticleId></ArticleIdList></Reference><Reference><Citation>Klimas J, Olvedy M, Ochodnicka-Mackovicova K, Kruzliak P, Cacanyiova S, Kristek F, Krenek P, Ochodnicky P. Perinatally administered losartan augments renal ACE2 expression but not cardiac or renal Mas receptor in spontaneously hypertensive rats. J Cell Mol Med. 2015;19(8):1965&#x2013;1974. doi: 10.1111/jcmm.12573.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.12573</ArticleId><ArticleId IdType="pmc">PMC4549047</ArticleId><ArticleId IdType="pubmed">25766467</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, Diz DI, Gallagher PE. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005;111(20):2605&#x2013;2610. doi: 10.1161/CIRCULATIONAHA.104.510461.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.104.510461</ArticleId><ArticleId IdType="pubmed">15897343</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuster GM, Pfister O, Burkard T, Zhou Q, Twerenbold R, Haaf P, Widmer AF, Osswald S. SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19. Eur Heart J. 2020;41(19):1801&#x2013;1803. doi: 10.1093/eurheartj/ehaa235.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehaa235</ArticleId><ArticleId IdType="pmc">PMC7184407</ArticleId><ArticleId IdType="pubmed">32196087</ArticleId></ArticleIdList></Reference><Reference><Citation>Zavascki AP, Falci DR. Clinical characteristics of Covid-19 in China. N Engl J Med. 2020;382:1859&#x2013;1862. doi: 10.1056/NEJMc2005203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2005203</ArticleId><ArticleId IdType="pubmed">32220202</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang CW, Chuang HC, Tan TH. ACE2 in chronic disease and COVID-19: gene regulation and post-translational modification. J Biomed Sci. 2023;30(1):71. doi: 10.1186/s12929-023-00965-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-023-00965-9</ArticleId><ArticleId IdType="pmc">PMC10464117</ArticleId><ArticleId IdType="pubmed">37608279</ArticleId></ArticleIdList></Reference><Reference><Citation>Balasuriya L, Briss PA, Twentyman E, Wiltz JL, Richardson LC, Bigman ET, Wright JS, Petersen R, Hannan CJ, Thomas CW, Barfield WD, Kittner DL, Hacker KA. Impacts of the COVID-19 pandemic on nationwide chronic disease prevention and health promotion activities. Am J Prev Med. 2023;64(3):452&#x2013;458. doi: 10.1016/j.amepre.2022.09.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amepre.2022.09.012</ArticleId><ArticleId IdType="pmc">PMC9574464</ArticleId><ArticleId IdType="pubmed">36347662</ArticleId></ArticleIdList></Reference><Reference><Citation>Varghese E, Samuel SM, Liskova A, Kubatka P, B&#xfc;sselberg D. Diabetes and coronavirus (SARS-CoV-2): Molecular mechanism of Metformin intervention and the scientific basis of drug repurposing. PLoS Pathog. 2021;17(6):e1009634. doi: 10.1371/journal.ppat.1009634.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1009634</ArticleId><ArticleId IdType="pmc">PMC8219155</ArticleId><ArticleId IdType="pubmed">34157054</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46(4):586&#x2013;590. doi: 10.1007/s00134-020-05985-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-020-05985-9</ArticleId><ArticleId IdType="pmc">PMC7079879</ArticleId><ArticleId IdType="pubmed">32125455</ArticleId></ArticleIdList></Reference><Reference><Citation>Schett G, Manger B, Simon D, Caporali R. COVID-19 revisiting inflammatory pathways of arthritis. Nat Rev Rheumatol. 2020;16(8):465&#x2013;470. doi: 10.1038/s41584-020-0451-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-020-0451-z</ArticleId><ArticleId IdType="pmc">PMC7304381</ArticleId><ArticleId IdType="pubmed">32561873</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghitea TC. Correlation of periodontal bacteria with chronic inflammation present in patients with metabolic syndrome. Biomedicines. 2021;9(11):1709. doi: 10.3390/biomedicines9111709.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines9111709</ArticleId><ArticleId IdType="pmc">PMC8615403</ArticleId><ArticleId IdType="pubmed">34829940</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu PP, Blet A, Smyth D, Li H. The science underlying COVID-19. Circulation. 2020;142(1):68&#x2013;78. doi: 10.1161/CIRCULATIONAHA.120.047549.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.047549</ArticleId><ArticleId IdType="pubmed">32293910</ArticleId></ArticleIdList></Reference><Reference><Citation>Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, Bi Z, Zhao Y. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020;109(5):531&#x2013;538. doi: 10.1007/s00392-020-01626-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00392-020-01626-9</ArticleId><ArticleId IdType="pmc">PMC7087935</ArticleId><ArticleId IdType="pubmed">32161990</ArticleId></ArticleIdList></Reference><Reference><Citation>Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China] Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41(2):145&#x2013;151. doi: 10.3760/cma.j.issn.0254-6450.2020.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.issn.0254-6450.2020.02.003</ArticleId><ArticleId IdType="pubmed">32064853</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao C, Cai Y, Zhang K, Zhou L, Zhang Y, Zhang X, Li Q, Li W, Yang S, Zhao X, Zhao Y, Wang H, Liu Y, Yin Z, Zhang R, Wang R, Yang M, Hui C, Wijns W, McEvoy JW, Soliman O, Onuma Y, Serruys PW, Tao L, Li F. Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study. Eur Heart J. 2020;41(22):2058&#x2013;2066. doi: 10.1093/eurheartj/ehaa433.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehaa433</ArticleId><ArticleId IdType="pmc">PMC7314067</ArticleId><ArticleId IdType="pubmed">32498076</ArticleId></ArticleIdList></Reference><Reference><Citation>Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Holman RR. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321(7258):412&#x2013;419. doi: 10.1136/bmj.321.7258.412.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.321.7258.412</ArticleId><ArticleId IdType="pmc">PMC27455</ArticleId><ArticleId IdType="pubmed">10938049</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrie JR, Guzik TJ, Touyz RM. Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms. Can J Cardiol. 2018;34(5):575&#x2013;584. doi: 10.1016/j.cjca.2017.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cjca.2017.12.005</ArticleId><ArticleId IdType="pmc">PMC5953551</ArticleId><ArticleId IdType="pubmed">29459239</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramakrishnan RK, Kashour T, Hamid Q, Halwani R, Tleyjeh IM. Unraveling the mystery surrounding post-acute sequelae of COVID-19. Front Immunol. 2021;12:686029. doi: 10.3389/fimmu.2021.686029.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.686029</ArticleId><ArticleId IdType="pmc">PMC8278217</ArticleId><ArticleId IdType="pubmed">34276671</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizvi AA, Kathuria A, Al Mahmeed W, Al-Rasadi K, Al-Alawi K, Banach M, Banerjee Y, Ceriello A, Cesur M, Cosentino F, Galia M, Goh SY, Janez A, Kalra S, Kempler P, Lessan N, Lotufo P, Papanas N, Santos RD, Stoian AP, Toth PP, Viswanathan V, Rizzo M, CArdiometabolic Panel of International experts on Syndemic COvid-19 (CAPISCO) Post-COVID syndrome, inflammation, and diabetes. J Diabetes Complications. 2022;36(11):108336. doi: 10.1016/j.jdiacomp.2022.108336.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jdiacomp.2022.108336</ArticleId><ArticleId IdType="pmc">PMC9534783</ArticleId><ArticleId IdType="pubmed">36228563</ArticleId></ArticleIdList></Reference><Reference><Citation>Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, Nigoghossian C, Ageno W, Madjid M, Guo Y, Tang LV, Hu Y, Giri J, Cushman M, Qu&#xe9;r&#xe9; I, Dimakakos EP, Gibson CM, Lippi G, Favaloro EJ, Fareed J, Caprini JA, Tafur AJ, Burton JR, Francese DP, Wang EY, Falanga A, McLintock C, Hunt BJ, Spyropoulos AC, Barnes GD, Eikelboom JW, Weinberg I, Schulman S, Carrier M, Piazza G, Beckman JA, Steg PG, Stone GW, Rosenkranz S, Goldhaber SZ, Parikh SA, Monreal M, Krumholz HM, Konstantinides SV, Weitz JI, Lip GYH, Global COVID-19 Thrombosis Collaborative Group, Endorsed by the ISTH, NATF, ESVM, and the IUA, Supported by the ESC Working Group on Pulmonary Circulation and Right Ventricular Function COVID-19 and thrombotic or thromboembolic disease: Implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(23):2950&#x2013;2973. doi: 10.1016/j.jacc.2020.04.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2020.04.031</ArticleId><ArticleId IdType="pmc">PMC7164881</ArticleId><ArticleId IdType="pubmed">32311448</ArticleId></ArticleIdList></Reference><Reference><Citation>Steffel J, Giugliano RP, Braunwald E, Murphy SA, Mercuri M, Choi Y, Aylward P, White H, Zamorano JL, Antman EM, Ruff CT. Edoxaban versus warfarin in atrial fibrillation patients at risk of falling: ENGAGE AF-TIMI 48 analysis. J Am Coll Cardiol. 2016;68(11):1169&#x2013;1178. doi: 10.1016/j.jacc.2016.06.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2016.06.034</ArticleId><ArticleId IdType="pubmed">27609678</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao MP, Vinereanu D, Wojdyla DM, Alexander JH, Atar D, Hylek EM, Hanna M, Wallentin L, Lopes RD, Gersh BJ, Granger CB. Clinical outcomes and history of fall in patients with atrial fibrillation treated with oral anticoagulation: insights from the ARISTOTLE trial. Am J Med. 2018;131(3):269&#x2013;275.e2. doi: 10.1016/j.amjmed.2017.10.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2017.10.036</ArticleId><ArticleId IdType="pubmed">29122636</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5):1094&#x2013;1099. doi: 10.1111/jth.14817.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14817</ArticleId><ArticleId IdType="pmc">PMC9906401</ArticleId><ArticleId IdType="pubmed">32220112</ArticleId></ArticleIdList></Reference><Reference><Citation>Magon A, Arrigoni C, Barello S, Graffigna G, Caruso R. Managing anticoagulation in the COVID-19 era between lockdown and reopening phases: Comment. Intern Emerg Med. 2021;16(7):2017&#x2013;2018. doi: 10.1007/s11739-021-02647-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11739-021-02647-6</ArticleId><ArticleId IdType="pmc">PMC7873665</ArticleId><ArticleId IdType="pubmed">33566279</ArticleId></ArticleIdList></Reference><Reference><Citation>Alkhameys S, Barrett R. Impact of the COVID-19 pandemic on England&#x2019;s national prescriptions of oral vitamin K antagonist (VKA) and direct-acting oral anticoagulants (DOACs): An interrupted time series analysis (January 2019-February 2021) Curr Med Res Opin. 2022;38(7):1081&#x2013;1092. doi: 10.1080/03007995.2022.2078100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/03007995.2022.2078100</ArticleId><ArticleId IdType="pubmed">35582854</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasan SS, Radford S, Kow CS, Zaidi STR. Venous thromboembolism in critically ill COVID-19 patients receiving prophylactic or therapeutic anticoagulation: a systematic review and meta-analysis. J Thromb Thrombolysis. 2020;50(4):814&#x2013;821. doi: 10.1007/s11239-020-02235-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-020-02235-z</ArticleId><ArticleId IdType="pmc">PMC7396456</ArticleId><ArticleId IdType="pubmed">32748122</ArticleId></ArticleIdList></Reference><Reference><Citation>DiNicolantonio JJ, McCarty M. Thrombotic complications of COVID-19 may reflect an upregulation of endothelial tissue factor expression that is contingent on activation of endosomal NADPH oxidase. Open Heart. 2020;7(1):e001337. doi: 10.1136/openhrt-2020-001337.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/openhrt-2020-001337</ArticleId><ArticleId IdType="pmc">PMC7298678</ArticleId><ArticleId IdType="pubmed">32532805</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrotta F, Corbi G, Mazzeo G, Boccia M, Aronne L, D&#x2019;Agnano V, Komici K, Mazzarella G, Parrella R, Bianco A. COVID-19 and the elderly: insights into pathogenesis and clinical decision-making. Aging Clin Exp Res. 2020;32(8):1599&#x2013;1608. doi: 10.1007/s40520-020-01631-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40520-020-01631-y</ArticleId><ArticleId IdType="pmc">PMC7298699</ArticleId><ArticleId IdType="pubmed">32557332</ArticleId></ArticleIdList></Reference><Reference><Citation>Boccia M, Aronne L, Celia B, Mazzeo G, Ceparano M, D&#x2019;Agnano V, Parrella R, Valente T, Bianco A, Perrotta F. COVID-19 and coagulative axis: review of emerging aspects in a novel disease. Monaldi Arch Chest Dis. 2020;90(2) doi: 10.4081/monaldi.2020.1300.</Citation><ArticleIdList><ArticleId IdType="doi">10.4081/monaldi.2020.1300</ArticleId><ArticleId IdType="pubmed">32425013</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>